[go: up one dir, main page]

MX347237B - Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. - Google Patents

Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.

Info

Publication number
MX347237B
MX347237B MX2013000851A MX2013000851A MX347237B MX 347237 B MX347237 B MX 347237B MX 2013000851 A MX2013000851 A MX 2013000851A MX 2013000851 A MX2013000851 A MX 2013000851A MX 347237 B MX347237 B MX 347237B
Authority
MX
Mexico
Prior art keywords
treatment
sexual dysfunction
female sexual
pharmaceutical formulations
female
Prior art date
Application number
MX2013000851A
Other languages
English (en)
Inventor
Johan Adriaan Tuiten Jan
Original Assignee
Eb Ip Lybrido B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35094148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347237(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eb Ip Lybrido B V filed Critical Eb Ip Lybrido B V
Publication of MX347237B publication Critical patent/MX347237B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Primary Health Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Business, Economics & Management (AREA)
  • Tourism & Hospitality (AREA)
  • Medicinal Preparation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Economics (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Strategic Management (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)

Abstract

La presente invención se relaciona con el uso de una combinación de un inhibidor de PDE5 y testosterona para la preparación de un medicamento para el tratamiento de la Disfunción Sexual Femenina.
MX2013000851A 2004-05-11 2005-05-11 Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. MX347237B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04076402 2004-05-11
EP04078033 2004-11-04
EP04078381 2004-12-13
EP04078380 2004-12-13
EP04078455 2004-12-21
PCT/NL2005/000355 WO2005107810A2 (en) 2004-05-11 2005-05-11 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
MX347237B true MX347237B (es) 2017-04-20

Family

ID=35094148

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013000851A MX347237B (es) 2004-05-11 2005-05-11 Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
MXPA06013133A MXPA06013133A (es) 2004-05-11 2005-05-11 Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA06013133A MXPA06013133A (es) 2004-05-11 2005-05-11 Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.

Country Status (22)

Country Link
US (5) US8227453B2 (es)
EP (1) EP1750766B1 (es)
JP (3) JP2007537247A (es)
KR (1) KR101292492B1 (es)
CN (2) CN101027061B (es)
AU (1) AU2005239962B2 (es)
BR (1) BRPI0511079A (es)
CA (1) CA2566699C (es)
CY (1) CY1114448T1 (es)
DK (1) DK1750766T3 (es)
ES (1) ES2429444T3 (es)
HK (1) HK1108128A1 (es)
HR (1) HRP20130892T1 (es)
MX (2) MX347237B (es)
NZ (1) NZ551356A (es)
PL (1) PL1750766T3 (es)
PT (1) PT1750766E (es)
RS (1) RS52945B (es)
RU (2) RU2436579C2 (es)
SI (1) SI1750766T1 (es)
WO (1) WO2005107810A2 (es)
ZA (1) ZA200609974B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005239962B2 (en) 2004-05-11 2011-07-07 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2012107092A1 (en) * 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107541A1 (en) * 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
EP2672959A1 (en) * 2011-02-10 2013-12-18 Synthon BV Granulated composition comprising tadalafil and a disintegrant
WO2012158030A2 (en) 2011-05-13 2012-11-22 Emotional Brain B.V. Drug delivery system
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
WO2013122470A1 (en) * 2012-02-17 2013-08-22 Emotional Brain B.V. Methods of differentiating hypoactive sexual desire disorder and/or female sexual arousal disorder
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR101484481B1 (ko) * 2014-08-07 2015-01-20 주식회사 다림바이오텍 Pde-5 저해제를 포함하는 설하분무제의 제조방법 및 이에 의하여 제조된 설하분무용 조성물
EP3248592A1 (en) * 2016-05-25 2017-11-29 EB IP Hybritabs B.V. Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systems
US20250073171A1 (en) * 2023-09-05 2025-03-06 Freya Pharma Solutions Holding B.V. Drug delivery system for the treatment of female sexual interest and arousal disorder

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
DK169601B1 (da) 1983-10-17 1994-12-19 Duphar Int Res Piperazinderivater og farmaceutisk præparat indeholdende et sådant derivat, samt piperazinderivater med mellemproduktanvendelse
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
RU2152787C2 (ru) 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
ATE184490T1 (de) 1994-06-02 1999-10-15 Dan Riga Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung
EP0814775A1 (en) 1995-03-14 1998-01-07 Vivus, Inc. Method and kit for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
AU5671496A (en) 1995-05-15 1996-11-29 Beth Israel Hospital Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
ATE315931T1 (de) 1997-06-23 2006-02-15 Cellegy Pharma Inc Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
CA2306837C (en) 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6246436B1 (en) 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
EP1173167A4 (en) 1999-04-30 2004-07-14 Lilly Icos Llc TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS
US6632419B2 (en) 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
EP1207902A2 (de) * 1999-06-17 2002-05-29 Pharmacia AB VERWENDUNG VON WACHSTUMSHORMON (hGH) ZUR THERAPIE SEXUELLER FUNKTIONSSTÖRUNGEN
RU2180591C2 (ru) 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
NZ524601A (en) 2000-08-30 2006-04-28 Unimed Pharmaceuticals Inc Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
AU2002223572B2 (en) 2000-09-29 2005-09-08 Abbvie B.V. Ion-strength independent sustained release pharmaceutical formulation
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
EE200300469A (et) 2001-03-28 2004-02-16 Pfizer Inc. N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
CA2532252A1 (en) 2003-07-16 2005-01-27 Pfizer Inc. Treatment of sexual dysfunction
DE60303854T2 (de) 2003-11-11 2006-08-10 Mattern, Udo Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
WO2005094827A1 (en) 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
CA2563743A1 (en) 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
AU2005239962B2 (en) 2004-05-11 2011-07-07 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
JP2008536851A (ja) 2005-04-13 2008-09-11 ユニメド ファーマスーティカルズ インク 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
SI2215072T1 (sl) 2007-11-28 2015-10-30 Ucb Pharma Gmbh Polimorfna oblika rotigotina

Also Published As

Publication number Publication date
RU2006143652A (ru) 2008-06-20
HRP20130892T1 (hr) 2013-11-08
EP1750766B1 (en) 2013-07-03
HK1108128A1 (en) 2008-05-02
JP2015071650A (ja) 2015-04-16
US20190388435A1 (en) 2019-12-26
KR20070042920A (ko) 2007-04-24
CY1114448T1 (el) 2016-10-05
US9192669B2 (en) 2015-11-24
JP6166739B2 (ja) 2017-07-19
RS52945B (en) 2014-02-28
MXPA06013133A (es) 2007-05-23
ZA200609974B (en) 2008-07-30
AU2005239962B2 (en) 2011-07-07
US20070093450A1 (en) 2007-04-26
ES2429444T3 (es) 2013-11-14
PT1750766E (pt) 2013-09-30
EP1750766A2 (en) 2007-02-14
NZ551356A (en) 2009-09-25
PL1750766T3 (pl) 2013-12-31
CA2566699A1 (en) 2005-11-17
KR101292492B1 (ko) 2013-08-01
WO2005107810A2 (en) 2005-11-17
JP2013177423A (ja) 2013-09-09
JP5923459B2 (ja) 2016-05-24
WO2005107810A3 (en) 2007-02-15
CN101027061B (zh) 2014-03-12
CN102512681A (zh) 2012-06-27
DK1750766T3 (da) 2013-10-14
US8227453B2 (en) 2012-07-24
US9700566B2 (en) 2017-07-11
SI1750766T1 (sl) 2013-11-29
RU2011133242A (ru) 2013-02-20
AU2005239962A1 (en) 2005-11-17
BRPI0511079A (pt) 2007-12-26
JP2007537247A (ja) 2007-12-20
CN101027061A (zh) 2007-08-29
US10441592B2 (en) 2019-10-15
CA2566699C (en) 2016-02-16
US20160015720A1 (en) 2016-01-21
US20170273989A1 (en) 2017-09-28
RU2436579C2 (ru) 2011-12-20
RU2636501C2 (ru) 2017-11-23
US20120264722A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
ZA200609974B (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
MX2013000001A (es) Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral.
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
TW200603807A (en) Method for the treatment of premenstrual and other female sexual disorders
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
IL191280A0 (en) Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
TW200716082A (en) Combination and use of drugs
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
PL1781292T3 (pl) Formulacja o przedłużonym uwalnianiu 3-amino-8-(1-piperazynylo)-2H-1-benzopiran-2-onu
MD3644F1 (en) Preparation for algodismenorrhea treatment
HK1073109A1 (en) Pharmaceutical composition for treatment of male sexual dysfunction
PL1817029T3 (pl) Pochodna izoksazolowa do łagodzenia bólu neuropatycznego
MY154883A (en) A combination composition
UA97950C2 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период